Sustained Myocarditis following Messenger RNA Vaccination against Coronavirus Disease 2019: Relation to Neutralizing Antibody and Amelioration by Low-Dose Booster Vaccination
We recently reported that sub-acute myocarditis occurred following the initial two doses of messenger RNA-based vaccination against coronavirus disease 2019 (0.3 mL Comirnaty<sup<®</sup<) in elderly Japanese patients with cardiac dysfunction. The present retrospective study of 76 patients revealed that myocarditis following the initial doses persisted for 12 months, was associated with low levels of neutralizing antibodies, and was ameliorated by reducing the third vaccine dose. Low neutralizing antibody levels (<220 U/mL) after the initial doses were an independent predictor of persistent clinical events, defined as death or marked changes in brain natriuretic peptide levels. When the third dose was reduced (0.1 mL), changes in brain natriuretic peptide levels were significantly smaller (<i<p</i< = 0.02, <i<n</i< = 25), no deaths occurred due to heart failure, and neutralizing antibody levels increased 41-fold (<i<p</i< < 0.001) compared with the initial doses. Reduced booster doses could facilitate the worldwide distribution of messenger RNA vaccines..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of Clinical Medicine - 12(2023), 4, p 1421 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Koji Miyazaki [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Coronavirus disease 2019 (COVID-19) |
|---|
| doi: |
10.3390/jcm12041421 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ080247725 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ080247725 | ||
| 003 | DE-627 | ||
| 005 | 20240413062841.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230310s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm12041421 |2 doi | |
| 035 | |a (DE-627)DOAJ080247725 | ||
| 035 | |a (DE-599)DOAJad02dae111534446a6062082112987a7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Koji Miyazaki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sustained Myocarditis following Messenger RNA Vaccination against Coronavirus Disease 2019: Relation to Neutralizing Antibody and Amelioration by Low-Dose Booster Vaccination |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a We recently reported that sub-acute myocarditis occurred following the initial two doses of messenger RNA-based vaccination against coronavirus disease 2019 (0.3 mL Comirnaty<sup<®</sup<) in elderly Japanese patients with cardiac dysfunction. The present retrospective study of 76 patients revealed that myocarditis following the initial doses persisted for 12 months, was associated with low levels of neutralizing antibodies, and was ameliorated by reducing the third vaccine dose. Low neutralizing antibody levels (<220 U/mL) after the initial doses were an independent predictor of persistent clinical events, defined as death or marked changes in brain natriuretic peptide levels. When the third dose was reduced (0.1 mL), changes in brain natriuretic peptide levels were significantly smaller (<i<p</i< = 0.02, <i<n</i< = 25), no deaths occurred due to heart failure, and neutralizing antibody levels increased 41-fold (<i<p</i< < 0.001) compared with the initial doses. Reduced booster doses could facilitate the worldwide distribution of messenger RNA vaccines. | ||
| 650 | 4 | |a coronavirus disease 2019 (COVID-19) | |
| 650 | 4 | |a vaccine | |
| 650 | 4 | |a myocarditis | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a neutralizing antibody | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Toshiharu Fujii |e verfasserin |4 aut | |
| 700 | 0 | |a Kikue Mori |e verfasserin |4 aut | |
| 700 | 0 | |a Ryuichi Tamimoto |e verfasserin |4 aut | |
| 700 | 0 | |a Hirofumi Nagamatsu |e verfasserin |4 aut | |
| 700 | 0 | |a Tsutomu Murakami |e verfasserin |4 aut | |
| 700 | 0 | |a Yasunori Cho |e verfasserin |4 aut | |
| 700 | 0 | |a Shinya Goto |e verfasserin |4 aut | |
| 700 | 0 | |a Hidezo Mori |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Clinical Medicine |d MDPI AG, 2013 |g 12(2023), 4, p 1421 |w (DE-627)DOAJ000006793 |x 20770383 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:4, p 1421 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/jcm12041421 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/ad02dae111534446a6062082112987a7 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2077-0383/12/4/1421 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2077-0383 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 4, p 1421 | ||